ACE-031 1mg Review

ACE-031 occupies a distinctive position in the landscape of muscle-biology research tools. Unlike small-molecule myostatin inhibitors or antisense approaches, ACE-031 is a soluble decoy receptor constructed from the extracellular ligand-binding domain of activin receptor type IIB (ActRIIB) fused to a human IgG1 Fc region. That design allows it to sequester multiple TGF-beta superfamily ligands simultaneously, producing skeletal-muscle hypertrophy signals that researchers can interrogate without relying on knockout animal models alone.

Acceleron Pharma (now part of Merck KGaA / Bristol Myers Squibb) advanced ACE-031 through Phase 1 and Phase 2 clinical trials before halting development following safety signals primarily related to vascular and mucosal side effects. The publicly available clinical data, alongside a substantial body of pre-clinical rodent and non-human primate work, makes ACE-031 one of the better-characterised research peptides in the ActRIIB-pathway space. That history also makes honest safety reporting non-negotiable.

This review compiles the peer-reviewed literature, contextualises the pharmacology, and evaluates the 1 mg research-grade vial offered by Apollo Peptide Sciences. Researchers working in sarcopenia models, Duchenne muscular dystrophy (DMD) preclinical assays, or muscle-wasting disease paradigms will find the depth of mechanism and study discussion most relevant.

Editor's Verdict

ACE-031 earns a strong recommendation as a research tool for investigators specifically studying ActRIIB-pathway biology. The mechanistic rationale is grounded in over two decades of TGF-beta superfamily research, the preclinical efficacy data in rodent and primate models is reproducible across independent laboratories, and the clinical dataset, although small and ultimately negative for safety, provides rare translational context that most research peptides simply lack.

The principal caveats are significant. First, the molecular weight (roughly 60-70 kDa as a glycoprotein Fc-fusion) means solubility and stability demands differ substantially from conventional small peptides. Second, the clinical programme's termination at Phase 2 was driven by telangiectasias, epistaxis, and gum bleeding in Duchenne muscular dystrophy patients, pointing to off-target effects on BMP-9/BMP-10-mediated vascular signalling. Any preclinical study design that ignores that signal is incomplete. Third, at $200.00 per milligram, cost-per-experiment is materially higher than comparator inhibitors such as follistatin 344 or GDF-8 propeptide.

Specifications

The vial size of 1 mg is the standard research unit for ACE-031. Because the compound is an Fc-fusion glycoprotein rather than a synthetic peptide, the fill weight reflects protein mass including glycan chains; researchers should verify the specific activity (pmol ligand bound per mg protein) on the CoA rather than relying on mass alone.

What It Is: Chemistry, Origin, and Sequence Detail

Structural architecture

ACE-031 is a recombinant fusion protein composed of the extracellular ligand-binding domain of human activin receptor type IIB (ActRIIB, gene symbol ACVR2B) linked to the Fc region of human immunoglobulin G1 (IgG1) ^[1]. The ActRIIB ectodomain spans approximately 117 amino acids and adopts a three-finger toxin fold characterised by a central beta-sheet core flanked by conserved cysteine residues that form disulfide bonds critical for ligand recognition ^[2]. The Fc fusion dimerises the construct, increasing effective size, extending circulatory half-life via neonatal Fc receptor (FcRn) recycling, and facilitating purification over protein-A columns.

The construct was developed at Acceleron Pharma as a strategy to simultaneously antagonise multiple pro-atrophy ligands within the TGF-beta superfamily, rather than targeting a single cytokine. This distinguishes ACE-031 architecturally from monoclonal antibodies such as landogrozumab (which binds myostatin specifically) or stamulumab, and positions it closer to the related molecule sotatercept (ACE-011), which targets the same receptor class but was advanced primarily for anaemia and pulmonary arterial hypertension indications ^[3].

Relationship to sotatercept and luspatercept

Sotatercept (ACE-011) uses the same ActRIIB-Fc scaffold but is glycoengineered differently and may present a slightly different ligand-binding profile in practice. Luspatercept (ACE-536) is a modified ActRIIB-Fc in which specific residues in the binding domain were altered to shift selectivity toward GDF-11 and activin B while reducing affinity for activin A ^[4]. Understanding where ACE-031 sits on that selectivity spectrum is important when designing experiments: ACE-031 retains broad-spectrum ligand trapping, which amplifies the anabolic signal but complicates mechanistic attribution.

Glycosylation and molecular heterogeneity

Because ACE-031 is expressed in mammalian cell culture (typically CHO or HEK293 systems for research-grade material), glycosylation patterns can vary between production lots. N-linked glycans attached at conserved asparagine residues account for roughly 15-20% of the molecular weight and directly influence thermal stability, solubility, and FcRn binding kinetics ^[5]. Researchers procuring the compound from research-peptide vendors should specifically request a glycoform analysis or at minimum a size-exclusion HPLC trace that confirms the expected molecular-weight distribution and rules out substantial aggregation.

Sequence background

The canonical human ACVR2B protein (UniProt Q13705) contains a signal peptide (residues 1-18), an extracellular domain (residues 19-137), a single-pass transmembrane helix, and an intracellular serine/threonine kinase domain. ACE-031 retains only the extracellular domain, truncated to prevent any transmembrane interaction, fused to IgG1-Fc starting at the hinge region. The resulting construct lacks kinase activity by design; it functions purely as a ligand sink ^[1].

Mechanism of Action

Receptor binding and the ActRIIB ligand family

ActRIIB belongs to the type II receptor arm of TGF-beta superfamily signalling. Under physiological conditions, the receptor sits on the cell surface where it captures circulating ligands including myostatin (GDF-8), GDF-11, activin A, activin B, and to varying extents BMP-9 and BMP-10 ^[6]. Ligand binding to ActRIIB triggers recruitment and transphosphorylation of type I co-receptors (ALK4, ALK5, or ALK7 for activins; ALK1 for BMP-9/BMP-10), which in turn phosphorylate intracellular SMAD proteins (SMAD2/3 for activin-class ligands; SMAD1/5/8 for BMP-class ligands) ^[7].

ACE-031 intercepts ligands before they can engage the cell-surface receptor. Because the soluble ectodomain retains nanomolar affinity for the same binding interface that the full-length receptor uses, ACE-031 competes effectively with endogenous ActRIIB at physiological ligand concentrations ^[2]. The Fc dimerisation produces an avidity effect: one molecule of ACE-031 presents two binding sites, geometrically enhancing capture efficiency relative to a monomeric ectodomain.

Downstream SMAD signalling in skeletal muscle

In skeletal muscle, the SMAD2/3 pathway is anti-hypertrophic. Myostatin activates SMAD2/3, which translocates to the nucleus and suppresses the expression of genes controlling protein synthesis, including those regulated by mTORC1 ^[8]. SMAD2/3 activation also elevates Atrogin-1 (MAFbx) and MuRF-1, two E3 ubiquitin ligases that drive proteasomal protein degradation ^[9]. By sequestering myostatin and activin A, ACE-031 reduces SMAD2/3 phosphorylation, tipping the balance of muscle protein turnover toward net synthesis.

The magnitude of this effect in preclinical models is substantial. In wild-type mice, a single subcutaneous injection of ActRIIB-Fc increased skeletal muscle mass by 15-25% over four to eight weeks, with the majority of gains attributable to fibre hypertrophy (increased cross-sectional area) rather than hyperplasia ^[10]. Parallel suppression of the SMAD2/3 axis by ACE-031 also reduces expression of the ubiquitin ligase transcriptional programme, providing a secondary anabolic mechanism independent of direct mTOR activation ^[8].

BMP pathway and vascular biology considerations

The vascular safety signals observed in clinical trials are mechanistically traceable to ActRIIB's role in BMP-9/BMP-10 signalling in the endothelium. BMP-9 and BMP-10 use ActRIIB as a co-receptor alongside ALK1 (encoded by ACVRL1) and endoglin to maintain vascular quiescence; loss-of-function mutations in this pathway are a recognised cause of hereditary haemorrhagic telangiectasia (HHT) ^[11]. ACE-031, by trapping BMP-9 and BMP-10 systemically, partially recapitulates the HHT biochemical phenotype, which is the most credible mechanistic explanation for the telangiectasia and mucosal bleeding observed in the DMD trial ^[12].

This pharmacological reality has direct experimental implications. Researchers using ACE-031 in rodent models should include BMP-9/ALK1 pathway readouts (pSMAD1/5/8 in lung and liver endothelial tissue, plasma BMP-9 levels) alongside the intended skeletal-muscle endpoints to fully characterise the biological footprint of the compound.

Tissue distribution of ActRIIB and relevance to research models

ActRIIB is expressed broadly: skeletal muscle, cardiac muscle, adipose tissue, bone, liver, and vascular endothelium all express the receptor at varying levels ^[6]. This broad expression explains why ACE-031 affects body composition globally rather than selectively. Rodent studies document concurrent reductions in fat mass alongside muscle-mass gains, an effect attributable at least partially to activin A sequestration in adipose progenitor cells ^[13]. Bone effects via GDF-11 and activin A trapping have been described in the sotatercept literature and are likely relevant to ACE-031 as well, given the shared receptor architecture ^[4]. Researchers focused on isolated muscle physiology should design appropriate controls to account for these systemic secondary effects.

What the Research Says

Study 1: Lee and colleagues (2005), foundational mouse hypertrophy model

Lee SJ and colleagues published the foundational study demonstrating that systemic administration of a soluble ActRIIB-Fc construct produced dramatic skeletal-muscle hypertrophy in adult mice ^[10]. The experimental design used wild-type C57BL/6 mice receiving weekly subcutaneous injections of the Fc-fusion at doses ranging from 1 to 10 mg/kg. Over an eight-week treatment period, total skeletal muscle mass increased by approximately 15-25% in treated animals relative to vehicle controls, with the gastrocnemius and quadriceps showing the most pronounced gains.

The mechanistic arm of the study used myostatin-null mice to establish that ActRIIB-Fc retained activity even in the absence of the canonical ligand, directly demonstrating that non-myostatin ligands (subsequently identified as activin A and GDF-11) contributed meaningfully to the anabolic response. This was a pivotal finding because it implied that myostatin-only inhibition strategies would capture only a fraction of the available anabolic signal from the ActRIIB pathway. The study's principal limitation was its exclusive focus on healthy wild-type and genetic-knockout animals; pathological atrophy models were not included, limiting direct translational inference.

The implications for researchers are significant. If a study design intends to use ACE-031 as a pure myostatin inhibitor, this Lee 2005 work establishes that the construct's biology is fundamentally broader. Experiments that fail to account for simultaneous activin A and GDF-11 suppression may mis-attribute observed effects to myostatin alone.

Study 2: Attie and colleagues (2013), Phase 1 clinical PK/PD in healthy postmenopausal women

Attie KM et al. published the first human pharmacokinetic and pharmacodynamic characterisation of ACE-031 following a randomised, double-blind, placebo-controlled single-dose Phase 1 trial in 48 healthy postmenopausal women ^[14]. Subjects received subcutaneous ACE-031 at doses from 0.01 to 3.0 mg/kg. Lean body mass, as measured by DXA, increased dose-dependently at doses above 0.3 mg/kg, with a mean increase of approximately 3% lean mass at the 1.0 mg/kg dose after 57 days.

Pharmacokinetically, the terminal half-life was estimated at approximately 9-11 days, consistent with FcRn-mediated recycling that extends half-life beyond a typical IgG antibody. Volume of distribution was low (approximately 4-5 L), indicating predominantly vascular and interstitial distribution without deep tissue sequestration. Serum biomarkers of ActRIIB-pathway activity, including follistatin and bone alkaline phosphatase, showed dose-dependent changes confirming target engagement.

The study reported three cases of telangiectasias at higher dose levels and one case of mild epistaxis. These signals, while not statistically powered as a safety study, prompted the escalation to Phase 2 with enhanced safety monitoring. The published data remain the only human pharmacokinetic dataset for ACE-031 and are essential reading for any researcher building a translational model.

Study 3: Campbell and colleagues (2017), DMD Phase 2 trial

Campbell C et al. published results from the Phase 2 randomised controlled trial of ACE-031 in boys with Duchenne muscular dystrophy ^[15]. The trial enrolled 53 participants (aged 6-14 years) randomised to placebo or ACE-031 at 0.1, 0.3, or 1.0 mg/kg subcutaneously every four weeks. The primary endpoint was change in total lean body mass at 24 weeks; secondary endpoints included muscle strength tests and MRI-based muscle fat infiltration measures.

Total lean body mass increased significantly in the 1.0 mg/kg arm (mean +2.1 kg, p=0.003 versus placebo). Fat infiltration scores on MRI were reduced in treated arms. However, functional strength improvements on the 6-minute walk test and other motor assessments did not reach statistical significance, raising the question of whether lean-mass gains translated to meaningful functional benefit within the trial's 24-week window.

The trial was terminated early following observation of serious adverse events including mucosal telangiectasias, epistaxis, and gum bleeding at rates that exceeded a pre-specified safety threshold. The Sponsor voluntarily discontinued the programme. This clinical history is the most relevant safety dataset for ACE-031 research use and underscores the mechanistically predicted vascular liability.

Study 4: Latres and colleagues (2015), activin A as a dominant atrophy mediator

Latres E et al. published a study that substantially reframed understanding of which ActRIIB ligands drive pathological muscle wasting in cachexia and sarcopenia models ^[16]. Using monoclonal antibody tools selectively targeting either myostatin or activin A in cancer cachexia mouse models, the authors demonstrated that activin A neutralisation, not myostatin neutralisation, was the dominant driver of muscle-mass preservation in cachectic animals.

This finding has direct relevance to ACE-031 research. Because ACE-031 sequesters both ligands simultaneously, it would be expected to outperform either monoclonal antibody alone in cachexia models, and the published data support this prediction. In direct comparisons, ActRIIB-Fc constructs consistently showed greater lean-mass preservation than myostatin-selective antibodies in tumour-bearing mice. The mechanistic implication is that researchers using ACE-031 to model cachexia attenuation are likely capturing activin A suppression as the primary biological driver, not myostatin suppression.

The study is limited by its reliance on a single cachexia model (Lewis lung carcinoma); the relative contributions of myostatin versus activin A may shift across different disease contexts, and the authors acknowledge that cardiac and fat-tissue effects of activin A trapping were not fully characterised.

Study 5: Becker and colleagues (2015), bone density and osteoblast biology

Becker C et al. evaluated the bone effects of ActRIIB-Fc treatment in ovariectomised mice, a standard osteoporosis model ^[17]. Animals receiving biweekly ActRIIB-Fc injections at 10 mg/kg demonstrated significant increases in trabecular bone volume (BV/TV +35% versus OVX-vehicle) and bone mineral density in both lumbar spine and femur after 10 weeks. Serum bone formation markers (osteocalcin, P1NP) were elevated, while bone resorption markers (CTX-1) were reduced, indicating a dual anabolic and anti-catabolic effect on bone.

The mechanism was attributed to sequestration of activin A and GDF-11, both of which suppress osteoblast differentiation via SMAD2/3 signalling in bone progenitor cells. This study is relevant for ACE-031 researchers because it establishes that bone effects are an expected secondary outcome of ActRIIB-Fc treatment, not an incidental observation. Any rodent study using ACE-031 at doses sufficient for muscle-mass changes should anticipate concurrent bone-density alterations that may influence endpoints such as body weight, fall-resistance assays, or fracture studies.

Study 6: Böhm and colleagues (2019), fat mass and metabolic regulation

Böhm M et al. examined body composition changes in mice treated with ActRIIB-Fc constructs, focusing specifically on adipose tissue responses ^[13]. A significant and dose-dependent reduction in fat mass accompanied the muscle-mass gains, with the magnitude of fat-mass reduction (roughly -20% of total fat mass at the highest dose) comparable in absolute terms to the muscle-mass gains. Adipose tissue biopsies showed reduced expression of adipogenic transcription factors (PPARgamma, C/EBP-alpha) and increased expression of lipolytic genes, suggesting that activin A sequestration in adipose progenitors shifts their differentiation programme.

This metabolic effect complicates the interpretation of body-weight endpoints in rodent studies using ACE-031. Total body weight may remain relatively stable because fat-mass reduction partially offsets lean-mass gain. Researchers relying on body weight as a proxy for compound efficacy will systematically underestimate the muscle-specific anabolic effect. DXA-based body composition or MRI is necessary to resolve this confound.

Pharmacokinetics

FcRn recycling and its implications for study design

The extended half-life of ACE-031 (9-11 days in humans, approximately 3-5 days in mice) derives almost entirely from FcRn-mediated neonatal Fc receptor recycling, the same mechanism that extends the half-life of therapeutic monoclonal antibodies ^[5]. FcRn is expressed in vascular endothelial cells and phagocytes; it rescues IgG-class proteins from lysosomal degradation by binding them at acidic endosomal pH and releasing them back to the bloodstream at neutral pH. This recycling loop means that ACE-031 accumulates over repeated dosing cycles, and researchers running multi-week protocols should anticipate a rise toward steady-state plasma concentrations rather than a flat dose-response.

In practice, rodent studies using weekly injections will see plasma concentrations approximately 3-4-fold higher by week 3-4 than after a single injection, assuming linear PK at the doses studied. This accumulation affects both the on-target efficacy (greater cumulative ligand trapping) and the off-target vascular risks. Dose-escalation studies in new animal models should incorporate single-dose PK characterisation before moving to repeat-dose efficacy protocols.

Route of administration considerations

The subcutaneous route is standard in both preclinical and clinical ACE-031 research because it approximates the slower-absorption profile associated with large Fc-fusion proteins ^[14]. Intravenous administration in rodent studies produces higher peak plasma concentrations (Cmax) for the same dose mass but similar area under the curve, with the subcutaneous Cmax roughly 30% lower and Tmax shifted 3-5 days later. For experiments requiring rapid receptor saturation (acute pharmacodynamic studies), IV delivery may be preferable. For chronic muscle-hypertrophy models, subcutaneous injection is preferred for its lower peak-concentration profile and more gradual receptor engagement.

Protein degradation and fragment detection

As an Fc-fusion glycoprotein, ACE-031 is catabolised by proteolytic enzymes at a rate determined partly by local injection-site tissue proteases and partly by systemic hepatic and renal clearance of liberated fragments. Unlike small synthetic peptides, the ACE-031 ectodomain fragment produced by Fc cleavage retains some ActRIIB-binding activity and may contribute to residual pharmacodynamic effects after Fc-mediated recycling decreases the intact molecule's concentration ^[2]. This has not been systematically characterised for research-grade material, and researchers should treat plasma half-life estimates as referring to the intact fusion protein rather than total ActRIIB-binding activity.

Purity and Verification

What to expect on a certificate of analysis

A certificate of analysis (CoA) for research-grade ACE-031 should minimally report: purity by non-reducing SDS-PAGE (expected single band at approximately 60-70 kDa under non-reducing conditions, consistent with the disulfide-linked homodimer); purity by size-exclusion HPLC (SEC-HPLC, monomer fraction ideally above 95%); endotoxin content by limulus amebocyte lysate (LAL) assay (acceptable threshold for cell culture work is below 1.0 EU/mg); residual host-cell protein (HCP) content if the vendor performs this test; and identity confirmation by peptide mapping or intact-mass measurement.

The SEC-HPLC trace is particularly informative for Fc-fusion proteins. High-molecular-weight aggregates (HMW species) appear as peaks eluting before the main monomer peak and indicate protein instability, cold-denaturation during shipping, or freeze-thaw damage. Aggregate fractions above 5% are associated with reduced specific activity and increased immunogenicity risk in cell-based assays ^[5]. Researchers should request the raw SEC-HPLC chromatogram, not just the summary purity percentage, to assess the shape of the aggregate distribution.

Independent verification approaches

For laboratories with access to analytical instrumentation, independent verification of ACE-031 can be performed by several methods. Intact-mass analysis by LC-MS confirms the molecular weight within approximately 0.01% mass accuracy, allowing detection of sequence truncations or non-canonical modifications. Reduced peptide mapping by tryptic digest followed by LC-MS/MS can confirm full coverage of the ActRIIB ectodomain sequence and identify any deamidation, oxidation, or clipping at known labile sites.

A more accessible functional verification uses a myostatin-reporter assay: C2C12 myoblasts transfected with a SMAD2/3-responsive luciferase construct are treated with recombinant myostatin in the presence and absence of ACE-031 serial dilutions. A well-characterised research-grade preparation inhibits myostatin-induced SMAD2/3 reporter activity with an IC50 in the low-nanomolar range (typically 1-10 nM in cell-based assays) ^[16]. If a batch's IC50 shifts more than twofold from a reference standard, activity has degraded.

For guidance on reading and interpreting CoA documents, see our supplier verification guide and disclosure page.

Dosage and Reconstitution

Reconstitution protocol for research-grade ACE-031

Because ACE-031 is a large glycoprotein, reconstitution requires more care than conventional synthetic peptides. Detailed technique guidance is available in our peptide reconstitution guide. The following summarises the key steps specific to Fc-fusion proteins.

Step 1, Temperature equilibration. Remove the lyophilised vial from -20°C storage and allow it to reach room temperature (approximately 20-22°C) before opening. Cold lyophilised protein is hygroscopic; introducing warm, humid air to a cold vial risks condensation inside the vial and protein degradation.

Step 2, Solvent selection. Sterile phosphate-buffered saline (PBS, pH 7.4) is the preferred reconstitution solvent for ACE-031 because the physiological ionic strength and pH stabilise the IgG1-Fc domain and minimise aggregation. Bacteriostatic water (containing benzyl alcohol) is not recommended for glycoprotein Fc-fusions because benzyl alcohol can denature the folded ectodomain at protein concentrations below 1 mg/mL. Sterile water for injection may be used if PBS is unavailable, but the resulting low-ionic-strength solution is less stable.

Step 3, Gentle addition and mixing. Add the reconstitution solvent slowly down the inner wall of the vial; do not inject directly onto the lyophilised cake. For a 1 mg vial reconstituted in 1 mL PBS, the target concentration is 1.0 mg/mL (1000 mcg/mL). Allow the vial to stand at room temperature for 5-10 minutes, then gently swirl (do not vortex). Vortexing Fc-fusion proteins at this concentration reliably generates aggregates.

Worked concentration examples

Example 1, 1 mg vial reconstituted to 500 mcg/mL. Add 2.0 mL PBS to the 1 mg vial. Each 100 mcL aliquot contains 50 mcg. For a rodent study using a literature-reported research dose of 10 mg/kg in a 25 g mouse (0.25 mg = 250 mcg), the required volume per injection is 500 mcL at this concentration.

Example 2, 1 mg vial reconstituted to 1 mg/mL. Add 1.0 mL PBS. Each 100 mcL aliquot contains 100 mcg. For the same 25 g mouse at 10 mg/kg, the required volume per injection is 250 mcL subcutaneously, which is at the upper acceptable limit for mouse SC dosing volume (typically 200-500 mcL depending on site). This concentration is therefore preferred for smaller injection volumes.

Example 3, In vitro cell assay dilution. Dissolve the 1 mg vial in 1.0 mL PBS to achieve 1 mg/mL stock. For a myostatin-reporter assay targeting an ACE-031 concentration of 100 nM in a 200 mcL well: the molecular weight of ACE-031 is approximately 60,000 g/mol, so 100 nM = 6.0 mcg/mL in the well. From the 1 mg/mL (1000 mcg/mL) stock, a 1:167 dilution is required. Add 1.2 mcL of stock to 198.8 mcL of assay medium. Serial dilutions for dose-response curves (e.g., 0.3, 1, 3, 10, 30, 100, 300 nM) are best prepared in polypropylene low-bind tubes to prevent surface adsorption.

For detailed dosage calculation methodology, see our dosage calculation guide.

Literature-reported research dosing ranges

In rodent skeletal-muscle hypertrophy studies, research protocols have used subcutaneous doses from 1 to 10 mg/kg administered weekly to biweekly over 4-8 weeks ^[10]. In the DMD Phase 2 clinical trial, subcutaneous doses of 0.1, 0.3, and 1.0 mg/kg every four weeks were evaluated in paediatric patients, with the 1.0 mg/kg arm showing the greatest lean-mass response alongside the most pronounced adverse-event profile ^[15]. In-vitro cell assays typically use ACE-031 in the range of 1-300 nM, with IC50 values for myostatin inhibition in the 1-10 nM range depending on the assay format ^[16].

Storage after reconstitution

Reconstituted ACE-031 should be aliquoted into single-use volumes immediately after reconstitution to avoid repeated freeze-thaw cycles. Each freeze-thaw cycle increases aggregate content by approximately 2-5% for typical Fc-fusion proteins ^[5]. Aliquots intended for use within 7 days can be stored at 4°C; longer-term storage should be at -20°C in a frost-free freezer. Avoid storage at -80°C without glycerol supplementation unless the vendor specifically validates this condition, as protein cryo-concentration during ice-crystal formation can drive aggregation.

Side Effects and Safety

Preclinical safety profile

In rodent studies, the dominant safety signals at research doses (1-10 mg/kg weekly) are bone marrow stimulation (erythrocytosis at higher doses, attributed to activin A sequestration in erythroid progenitors), enlargement of the heart (attributable in part to GDF-11 suppression, which normally maintains cardiac homeostasis), and vascular abnormalities at the highest doses ^[12]. Cardiac hypertrophy in rodents receiving ActRIIB-Fc constructs is pathologically distinct from exercise-induced physiological hypertrophy; it is accompanied by fibrosis markers in some protocols, making it a genuine safety concern rather than an incidental body-weight confound ^[17].

Hepatotoxicity has not been consistently observed at research doses, though liver enzyme elevations were reported at the highest doses in some preclinical screens. Reproductive toxicity data are limited; given that activin A plays a documented role in reproductive biology (folliculogenesis, placentation), researchers working with reproductively active animals should include fertility and embryo-development endpoints or use separated, non-breeding cohorts.

Clinical adverse event profile

The Phase 1 study in postmenopausal women identified telangiectasias in 3 of the 48 subjects at doses of 1.0 mg/kg and above; these were cutaneous lesions affecting the face and upper trunk, consistent with HHT-like biology ^[14]. In the Phase 2 DMD trial, mucosal involvement (gum bleeding, epistaxis) was additionally observed at rates statistically distinguishable from placebo. No deaths were attributable to study drug, and the telangiectasias observed were described as resolving or stable after treatment cessation, but the programme was halted before long-term follow-up data were available ^[15].

The clinical dataset is too small to characterise rare serious events or long-term cardiovascular risk. Researchers using ACE-031 in any context should be cognisant that the molecule has a documented human adverse-event profile that distinguishes it from many research peptides where clinical data are entirely absent.

Safety implications for cell-based and in-vitro research

At concentrations used in cell-based assays (1-300 nM), cell-autonomous cytotoxicity has not been reported in standard myoblast or endothelial cell lines. However, endothelial cells expressing ALK1 (HUVEC, HBMEC) are a particularly sensitive model system for detecting the BMP-9/ALK1 disruption effects of ACE-031; researchers using these lines should include BMP-9/ALK1-responsive gene expression readouts (e.g., ID1, SMAD1/5/8 phosphorylation) as part of their phenotypic characterisation.

How It Compares: ACE-031 vs Related Compounds

Relative positioning of ACE-031 in muscle-biology research

Among the ActRIIB-pathway research tools listed in the comparison table, ACE-031 produces the largest preclinical muscle-mass effect because of its breadth of ligand coverage. Its principal disadvantage relative to modified constructs (such as the R64/R65 ActRIIB-Fc variant) is exactly that breadth: it is the least mechanistically selective option, which makes it valuable for maximal pathway blockade studies and less useful for experiments attempting to isolate individual ligand contributions.

Researchers aiming to parse myostatin versus activin A contributions to muscle atrophy are better served by pairing ACE-031 with selective antibody tools (e.g., including a myostatin-specific antibody arm alongside an ACE-031 arm), rather than relying on ACE-031 alone. The Latres et al. 2015 study design exemplifies this approach ^[16].

Luspatercept and sotatercept are approved pharmaceuticals whose research-grade equivalents are available from commercial sources but typically at higher cost and with more stringent documentation requirements. Their approved status provides a safety benchmark: the ActRIIB-Fc scaffold is not inherently incompatible with human use when selectivity is engineered to reduce BMP-9/10 trapping. ACE-031's clinical discontinuation was a selectivity problem, not an indictment of the scaffold class.

Follistatin 344 represents a lower-cost alternative for studies primarily interested in activin A suppression in muscle, with less off-target vascular biology. However, follistatin 344 has shorter in-vivo half-life and more complex biology (it also binds BMP-7, heparan sulfate proteoglycans, and activin B) that may introduce its own interpretive challenges.

Where to Buy

Apollo Peptide Sciences lists ACE-031 at $200.00 per 1 mg vial. The vendor provides CoA documentation for each batch. For a full evaluation of their purity claims, quality-control practices, and order logistics, see our ACE-031 review page at Apollo Peptide Sciences, which includes the latest batch CoA analysis and an independent purity assessment.

For a broader comparison of research-peptide vendors, including quality ratings, payment processing, cold-chain shipping practices, and customer service scores, see our supplier comparison guide.

At $200.00 per milligram, ACE-031 is priced at the premium end of the research-peptide market, reflecting the cost of mammalian-cell expression, purification, and quality-control testing for a glycoprotein Fc-fusion. Researchers should budget approximately 2-4 vials per arm for a standard rodent efficacy study (depending on animal count and dosing interval), making total per-arm costs $400-800 for the compound alone.

Pharmacological Context: The TGF-beta Superfamily and Muscle Homeostasis

Evolutionary conservation of ActRIIB signalling

The activin receptor type IIB pathway is one of the most evolutionarily conserved muscle-regulatory mechanisms in vertebrates. Orthologues of myostatin and ActRIIB are present across all jawed vertebrates, and natural loss-of-function mutations in myostatin produce the double-muscling phenotype documented in Belgian Blue cattle, Texel sheep, whippet dogs, and, in rare cases, humans ^[8]. The consistent phenotype across species confirms that the pathway represents a genuine regulatory constraint on muscle mass rather than a species-specific mechanism.

The conservation also implies that the pathway interacts with other conserved systems. ActRIIB signalling intersects with the IGF-1/PI3K/mTOR anabolic axis, the androgen receptor pathway, and the NF-kB inflammatory pathway. Under conditions of simultaneous ActRIIB blockade and androgen receptor activation (as occurs when ACE-031 is tested in testosterone-replete male rodents), effects on muscle mass are additive rather than simply redundant, suggesting independent downstream mediators ^[9].

Satellite cell biology and regenerative capacity

A separate but related dimension of ActRIIB-pathway biology concerns satellite cells, the skeletal-muscle stem-cell population responsible for post-injury regeneration. Myostatin and activin A both suppress satellite-cell activation and self-renewal; ActRIIB blockade in injured muscle models accelerates satellite-cell proliferation and differentiation, enhancing regenerative capacity beyond the hypertrophy effect seen in uninjured muscle ^[18]. This regenerative dimension is particularly relevant to DMD research, where impaired regeneration contributes to progressive replacement of muscle by fibrofatty tissue.

The Fc-fusion construct's long half-life means that a single injection around the time of injury can maintain ActRIIB blockade through the entire early regenerative window (the first 7-14 days after injury is the critical period for satellite-cell involvement). This pharmacokinetic advantage over shorter-lived inhibitory peptides is one rationale for using ACE-031 rather than follistatin or propeptide constructs in acute-injury protocols.

Interaction with the GH/IGF-1 axis

The article's tag as a "gh-secretagogue" adjacent compound warrants clarification. ACE-031 does not directly stimulate growth hormone release and has no known direct activity at GH receptor or GHS-R1a. The "gh-secretagogue" category designation reflects commercial convention in the research-peptide market, where compounds producing lean-mass gain by any mechanism are sometimes grouped together. The mechanistic distinction matters for experimental design: ACE-031's anabolic effects are GH-independent, making it a useful comparator arm in studies attempting to disambiguate GH-axis-dependent from GH-axis-independent routes to muscle hypertrophy ^[10].

In hypophysectomised animals (which lack endogenous GH and IGF-1), ActRIIB-Fc constructs retain muscle-anabolic activity, whereas GH secretagogues show dramatically attenuated effects ^[6]. This experimental separation confirms mechanistic independence and validates ACE-031 as a tool for parsing the respective contributions of these two major anabolic signalling systems in muscle-biology research.

FAQ